In this review, we summarize the role of β 2 -adrenergic receptors in the alveolar epithelium with emphasis on their role in regulation of alveolar active Na + transport in normal and injured lungs. We also overview data regarding β 2 -agonist therapy for pulmonary edema and lung injury.
β-ADRENERGIC RECEPTORS

Subtypes and distribution in the lung
β-adrenergic receptors are ubiquitous throughout the human body and are classified into three distinct subtypes, β  , β 2 , and β 3 on the basis of their function, agonist binding patterns and genetics. (Table 1 ) There is 65-70% homology among the β 1 -, β 2 -, and β 3 -receptors. The β 3 -receptor is found primarily in adipocytes but is also present in pulmonary endothelial cells. The proposed β 4 -receptor appears to be a conformational state of β 1 -receptor in myocardial cells (2) . Neither the β 3 or β 4 receptors have been linked with regulation of ion transport in epithelial cells. 4 In the lung, β2-adrenergic receptor (β 2 AR) expression increases with each airway generation, with the greatest total amounts in the distal airways and alveoli (3) . Greater than 90% of all β-adrenergic receptors in human lung are located in the alveoli (4) . Although both β 1 and β 2 subtypes coexist and are distributed uniformly in the alveolar walls, the β 2 -subtype predominates (70%) (4) .
Isolated rat alveolar type II cells possess β 2 AR and data from autoradiographic and immunohistochemical studies support their presence in the alveolar type 1 cells (4, 5) . Activation of β 2 AR results in a variety of distinct signaling events besides activation of adenylyl cyclase. GRK2 phosphorylation of β 2 AR allows for binding of β-arrestins to the receptor, which uncouples the receptor from Gs, and promotes receptor endocytosis via clathrin coated vesicles (11) . Phosphorylation of β 2 AR also promotes signaling via Giβγ with subsequent downregulation of adenylyl cyclase activity and activation of mitogen-activated protein kinase (p44/p42). Both of these inhibitory pathways are important for regulation of Na,KATPase trafficking and function in alveolar epithelial cells (12) (13) (14) . ligands and as such quantification of agonist activity in terms of cAMP production may no longer be relevant (7) .
ROLE OF ALVEOLAR EPITHELIAL β 2 -ADRENERGIC RECEPTORS
Regulation of alveolar active Na + transport β 2 -adrenergic receptors, via cAMP dependent and independent pathways, regulate several of the key proteins needed for alveolar epithelial ion and fluid transport including amiloride-sensitive epithelial Na+ channels, the cystic fibrosis transmembrane conductance regulator (CFTR) and the Na, K-ATPase (36). The initial observation by Goodman and Crandal showing β-agonist induced active transcellular ion flux in confluent monolayers of isolated rat alveolar epithelial cells (37) was followed by many studies from isolated rat lungs (38) and anesthetized sheep (39) demonstrating that β-adrenergic agonists might be useful for the treatment of pulmonary edema.
Endogenous and exogenous catecholamines stimulate alveolar fluid clearance in newborn and adult animals via activation of β-receptors. Nonspecific βAR (isoproterenol, epinephrine, dobutamine) and β 2 AR specific agonists 7 (procaterol, salmeterol, terbutaline) increase alveolar fluid clearance in normal rat (40) , dog (41) , sheep (42) , guinea pig (43) , and mouse lungs (44, 45) and in human lung tissue (46) . β 2 -receptors appear to be responsible for the bulk of the β-receptor-sensitive alveolar active Na + transport (9) . Activation of the β 1 -adrenergic receptor can accelerate alveolar active Na + transport (47) , however data from studies in β 2 AR knockout mice suggest that the β 2 AR is responsible for most of the β-adrenergic mediated upregulation of AFC in fluid-filled lungs (9).
β-receptor-mediated increases in alveolar active Na individual Na,K-ATPases. These mechanistic findings suggest that upregulation of Na,K-ATPase activity by β 2 -receptor signaling is a complex process that occurs primarily through increased number of Na + pumps in the cell membrane rather than increased activity of individual pumps. The concentration of cAMP in the cell is determined by the activities of adenylyl cyclases and phophodiesterases, which inactivate cAMP (73) . There are 9 types of adenylyl cyclases, which are all transmembrane proteins, synthesizing cAMP at the plasma membrane (73, 74) . This results in a gradient where higher concentrations of cAMP are found at the membrane and lower concentrations in the cytosol (73, (75) (76) (77) (78) . This gradient may allow localization of the physiologic effect of βAR and resultant production of cAMP to microenvironments, which in turn activate specific target proteins.
Maintenance of alveolar fluid homeostasis
Recent data provides some clues regarding whether β 2 AR are required for maintenance of alveolar fluid balance in the normal lung (39, 41, 44-46, 79, 80) .
While initial studies of adrenalectomized animals (8, 45) or desensitization of β-receptors (81, 82) note no net effect on lung water content or basal alveolar fluid clearance, a more recent study showed reduced basal alveolar fluid clearance in adrenelectomized mice (83) . The differences between these studies may be due 11 to inability to fully desensitize alveolar β 2 -receptors or completely eliminate serum catecholamines and methods used to quantify alveolar fluid clearance (in vivo live model vs. ex vivo). Data from mice with no functional β 2 -receptor (β 2 -knockout) or β 1 -receptor and β 2 -receptor (β 1 β 2 -knockout) (9) similarly reveal normal water content when uninjured but decreased ability to clear excess water from the airspace and more pulmonary edema and decreased survival from acute lung injury (hyperoxia). These findings suggest that the β 2 AR is functionally required in the presence of excess airspace fluid but may not be required to maintain lung fluid balance in the uninjured lung or when fluid shifts are modest.
Importantly, these data indicate that other regulatory pathways are not sufficient to accelerate alveolar active Na + transport mechanisms in the injured lung.
Other functions
The effects of β-adrenergic receptor in the alveolar epithelium are not limited to upregulation of active Na + transport. β 2 -adrenergic receptor may also increase levels of the Wnt pathway member β-catenin, which regulates cell-tocell adhesions via cadherin (84, 85) . Phosphorylation of β-catenin by PKA stabilizes β-catenin post-translationally through inhibition of its ubiquitination (86) .
Experimental data also suggest that β-agonists can improve endothelial barrier function (87-89) by inhibition of endothelial cell contraction and reduced intracellular gap formation (90, 91) . β 2 AR also regulate surfactant secretion by alveolar type II cells (92, 93) . These additional effects may be responsible for some of the protective effects of β 2 -agonists in the acutely injured lung. 12 In contrast to the beneficial effects of β 2 -agonists on the alveolar epithelium, activation of β 2 AR, (94) has an inhibitory effect on the function of alveolar macrophages where they diminish motility (95) via increased levels of cAMP, which has also been reported to result in diminished fluid phase endocytosis (96) and phagocytosis function (97) .
-AGONIST THERAPY FOR TREATMENT OF PULMONARY EDEMA Experimental studies
There is a great body of experimental data indicating that specific and non-specific β-agonists enhance AFC in experimental models of cardiogenic and non-cardiogenic pulmonary edema (1, 9, 61) . Recent data suggest that These effects were attributed, in part to, improved responsiveness to endogenous catecholamines. Importantly, overexpression of the β 2 -receptor in mouse lungs markedly improved survival of mice exposed to 100% oxygen.
Clinical studies
Pulmonary edema clearance is impaired in animal models of hydrostatic and non-cardiogenic pulmonary edema (102, 103) . Loss of the ability to increase clearance of pulmonary edema is associated with increased risk of pulmonary edema and mortality from acute lung injury in humans (104) (105) (106) and animals (9).
In a study of 79 patients with ALI, greater than half had impaired pulmonary edema clearance and only 13% had maximal expected clearance rate (106). Limited clinical data regarding the use of β-agonists for pulmonary edema has expanded in the last few years. Salmeterol, a long-acting β 2 -agonist, has been shown to reduce the incidence of high-altitude pulmonary edema in mountain climbers when used as preventive therapy (104) . Aerosol delivery of albuterol at clinically approved doses to mechanically ventilated patients with respiratory failure yields clinically significant levels of this β-agonist in lung edema fluid (108) . Furthermore, β-agonist use correlates with improved outcome in patients with acute lung injury (109) . In a single center, double-blind, randomized controlled trial (BALTI, The β-Agonist Lung Injury Trial), treatment with intravenous salbutamol (15 μg/kg/hour) in patients with ARDS significantly lowered extravascular lung water content measured by thermodilution at day 7 compared to placebo (110) . Patients who received salbutamol had improved respiratory system compliance and a trend towards lower lung injury scores at day 7. In contrast to experimental data (89, 111) , the effect of β-agonist therapy on lung water content was not evident until 48 hours after initiation of therapy.
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The mechanism responsible for this delay in β-agonist response might be linked to alveolar epithelial damage during early ARDS (110) .
Limitations
The question of whether the alveolar epithelium may be critically injured and even denuded interfering with and offsetting the beneficial effects of β-agonists on the alveolar epithelium remains unanswered (36) . As such, it is unclear whether β 2 AR-mediated upregulation of active Na + transport is possible during severe lung injury. Some experimental ALI models (i.e., prolonged Theoretically, a potential limitation of β 2 -agonist therapy for treatment of pulmonary edema is receptor desensitization (a regulated process which leads to attenuation of the biologic effect of receptor during prolonged agonist exposure) and downregulation (a form desensitization during which density/number of receptors decreases), both of which will diminish the efficacy of β-agonist therapy (82, 118, 119) .
Regulation of β 2 -receptors occurs primarily through phosphorylation dependent loss of sensitivity to agonist. These processes have been extensively studied in cardiac cells and airway smooth muscle cells. Proclivity for desensitization varies among tissues, for example cardiac myocytes are readily desensitized whereas airway smooth muscle cells may not have the necessary G-protein coupled receptor kinases to affect receptor phosphorylation.
Continuous stimulation with isoproterenol causes impairment in the ability of β-agonists to increase alveolar fluid clearance only when non-specific β-agonists (isoproterenol) or high doses of a β 2 -agonist are used (120, 121) .
Prolonged stimulation with a β-agonist impairs its ability to continue to upregulate alveolar fluid clearance likely due to reduction in receptor density (121) and impaired of post-receptor signaling (82) . A broad base of data supports β-agonist-induced attenuation of β 2 AR mediated airway relaxation. Whether similar agonist dependent (homologous) or independent (heterologous) desensitization 17 occurs in alveolar epithelial cells in humans is not known, thus the implications of prolonged β 2 AR engagement on the protective effects of β-agonists is not known.
Another potentially limiting factor for use of β 2 -agonists is the β 2 -adrenergic receptor polymorphism, which might influence the response to the agonists and β 2 AR regulation (122, 123) . While the effect of β 2 -adrenergic receptor polymorphism in asthma has been studied and has been shown to affect clinical response, it has not been evaluated in the alveolar epithelium of humans (124) (125) (126) (127) .
Lastly, it is important to recognize the detrimental effects of β 2 -agonist therapy such as induction of tachycardia and increased oxygen consumption, which may cause adverse effects particularly in patients with underlying cardiovascular disease. Another concern is the worsening of ventilation perfusion mismatch that results from β-agonist mediated vasodilation, which precedes bronchodilation and thereby causes deterioration of oxygenation. Non-specific agonists include isoproterenol, norepinephrine and epinephrine Non-selective antagonists include propranol
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